Adaptimmune治疗公共 ADAP 深 沪
已收盘 10-27 16:00:00 美东时间
0.0549
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0549
- 总市值 889.38万
- 52周最高 0.8334
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.0403
- 委 比 0.00%
- 总股本 1.62亿
- 历史最高 21.57
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.0403
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Context Therapeutics appoints Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin brings over a decade of experience in T cell therapy development, including leading the approval of Tecelra® at Adaptimmune. She succeeds Dr. Karen Smith, who will remain on the Board.
05-29 11:30
Argenx to Present New Data on VYVGART's Long-Term Benefits for Autoimmune Patients at AAN Annual Meeting
argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for
03-07 15:48
